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Extended abstract
Introduction: Diabetes mellitus is one of the most common met-
abolic diseases worldwide. In type I diabetes, patient cannot pro-
duce insulin. Cell therapy by differentiating stem cells into insulin
producing cells (IPCs) and transplantation of IPCs to the patient
seems to be a promising therapeutic approach for type I diabetes
mellitus. Among different source of stem cells (including embry-
onic, induced pleuripotent and adult stem cells) mesenchymal
stem cells have some benefits over them; including less rejection
and immunomodulatory properties. A big obstacle against cell ther-
apy is the risk of tumorigenesis due to association of undifferenti-
ated cells after transplantation. Curcumin from Curcuma longa
plant has a variety of therapeutic properties (including anticancer,
antioxidant, anti-inflammatory and etc) and it has been widely uti-
lized in medicine. Beside these wonderful properties, curcumin is
unsolvable in water. Using di block nanocarrier, we obtained a solu-
ble curcumin-nanocarrier complex (nanocurcumin). We used this
nanocurcumin to target undifferentiated remaining cells after differ-
entiating hMSCs into IPCs.
Materials and methods: The medium used for culturing SCs was
Dullbecco’s modified Eagle’s medium (DMEM-low/high glucose),
with 10% fetal bovine serum (FBS) plus 100mg/ml streptomycin
and 100U/ml penicillin (all from Gibco BioCult, Paisley, Scotland,
UK). Phosphate-buffered saline (PBS) and trypsin-0.25% EDTA
were also purchased from Gibco BioCult. Total RNA was isolated
from cells using TRIzol reagent (Invitrogen) followed by DnaseI
treatment. DTZ and DMSO were provided from Merck (Germany).
2,5-diphenyltetrazolium bromide (MTT), agarose, and other reagents
were from Sigma-Aldrich (USA). All statistical analysis performed
by GraphPad Prism software (version 5.00). Error bars represent
mean ± SD.
Results: After differentiating stem cells into IPCs, fibroblast like
stem cells underwent morphological change; and formed grape-Fig. 2. Staining IPCs by DTZ (40X).shaped clusters (Figure 1). After staining by DTZ (a kind of chelator),
insulin producing clusters became crimson red (Figure 2). Real-time
PCR data showed that these clusters were able to produce insulin
(Figure 3). After differentiation we would have heterogeneous popu-
lation containing differentiated and undifferentiated cells (Figure 1).
Nestin is a stemness molecular marker which is expressed only by
undifferentiated/progenitor stem cells. After treating with nanocurcu-
min, the expression of this gene vanished among treated samples; and
other samples (including DNC- and control samples) yet expressed
nestin (Figure 4).
Discussion: Our data indicates that polymeric nanocurcumin
eradicated undifferentiated cells with no significant effect on insu-
lin expression level. And hence nanocurcumin can be introduced
as an efficient compound to be utilized in diabetes type I cell
therapy.
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Fig. 1. After differentiation treatment, homogenous population of undifferen-
tiated (fibroblast like cells) and differentiated (grape-shaped clusters of IPCs in
the middle of picture) cells emerges.
Fig. 3. Relative expression of insulin gene in different samples (DNC+: stem
cells which had differentiation and nanocurcumin treatment; DNC-: stem cells
which had differentiation treatment; Control: stem cells). p¼ 0.05.
Fig. 4. Nestin expression vanishes after treated by nanocurcumin (Normal:
stem cells at passage 5 with no treatment).
